Table 1.
Patient characteristics according to ANA titer.
| Variables | All patients n = 266 (%) | ANA<40 n = 147 (%) | ANA≧40 n = 119 (%) | p-value | ANA<80 n = 239 (%) | ANA≧80 n = 27 (%) | p-value |
|---|---|---|---|---|---|---|---|
| Age [Median] | 69 (31–86) | 69 (31–86) | 69 (39–84) | 69 (31–86) | 69 (43–79) | ||
| Gender Male/Female |
204/62 (76.7/23.3) |
109/38 (74.1/25.9) |
95/24 (79.8/20.2) |
0.31 | 183/56 (76.6/23.4) |
21/6 (77.8/22.2) |
0.99 |
| PS 0–1/Above 2 |
217/49 (81.6/18.4) |
121/26 (82.3/17.7) |
96/23 (80.7/19.3) |
0.75 | 194/45 (81.2/18.8) |
23/4 (85.2/14.8) |
0.80 |
| Smoking history Former/Never |
217/49 (81.6/18.4) |
115/32 (78.2/21.8) |
102/17 (85.7/14.3) |
0.15 | 192/47 (80.3/19.7) |
25/2 (92.6/7.4) |
0.19 |
| Histology Adeno/Squamous/Others |
150/67/49 (56.4/25.2/18.4) |
79/41/27 (53.7/27.9/18.4) |
71/26/22 (59.7/21.8/18.5) |
0.51 | 132/61/46 (55.2/25.5/19.2) |
18/6/3 (66.7/22.2/11.1) |
0.47 |
| Disease stage III/IV/Recurrence |
45/172/49 (16.9/64.7/18.4) |
22/95/30 (15.0/64.6/20.4) |
23/77/19 (19.3/64.7/16.0) |
0.50 | 38/156/45 (15.9/65.3/18.8) |
7/16/4 (25.9/59.3/14.8) |
0.42 |
| Radiotherapy Radical/Palliative/None |
40/65/161 (15.0/24.4/60.5) |
25/37/85 (17.0/25.2/57.8) |
15/28/76 (12.6/23.5/63.9) |
0.53 | 35/61/143 (14.6/25.5/59.8) |
5/4/18 (18.5/14.8/66.7) |
0.42 |
| Driver mutation Wild type/EGFR or ALK |
225/41 (84.6/15.4) |
120/27 (81.6/18.4) |
105/14 (88.2/11.8) |
0.17 | 200/39 (83.7/16.3) |
25/2 (92.6/7.4) |
0.40 |
| PD-L1 (TPS) <1%/1–49%/≥50%/Unknown |
10/15/63/178 (3.8/5.6/23.7/66.9) |
5/9/30/103 (3.4/6.1/20.4/70.1) |
5/6/33/75 (4.2/5.0/27.7/63.0) |
0.53 | 10/14/56/159 (4.2/5.9/23.4/66.5) |
0/1/7/19 (0.0/3.7/25.9/70.4) |
0.91 |
| Treatment lines 1st/2nd/Above 3rd |
55/138/73 (20.7/51.9/27.4) |
25/83/39 (17.0/56.5/26.5) |
30/55/34 (25.2/46.2/28.6) |
0.17 | 50/124/65 (20.9/51.9/27.2) |
5/14/8 (18.5/51.9/29.6) |
0.94 |
PS, performance status; ANA, antinuclear antibody; RT, radiotherapy; EGFR, epidermal growth factor receptor; ALK, Anaplastic lymphoma kinase; TPS, Tumor Proportion Score; adeno, adenocarcinoma; squamous, squamous cell carcinoma; PD-L1, programmed death ligand-1; Recurrence, recurrence after surgical resection.